Treatment with the selective P2X7 antagonist A-438079 markedly reduced cardiomyocyte hypertrophy, myocardial fibrosis, and inflammatory markers, and improved diastolic function and exercise capacity. This evidence concerns the gene P2RX7 and Myocardial fibrosis.